These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8124209)

  • 1. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
    Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
    Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
    Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
    Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
    Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
    Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
    Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
    Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
    Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
    Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.
    Moreland LW; Sewell KL; Trentham DE; Bucy RP; Sullivan WF; Schrohenloher RE; Shmerling RH; Parker KC; Swartz WG; Woodworth TG
    Arthritis Rheum; 1995 Sep; 38(9):1177-86. PubMed ID: 7575710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.
    Hesketh P; Caguioa P; Koh H; Dewey H; Facada A; McCaffrey R; Parker K; Nylen P; Woodworth T
    J Clin Oncol; 1993 Sep; 11(9):1682-90. PubMed ID: 8355035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
    Carretero-Margolis CD; Fivenson DP
    J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
    Kazin R; Bujanauskas P; Vonderheid EC
    J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
    Assaf C
    Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.
    LeMaistre CF; Craig FE; Meneghetti C; McMullin B; Parker K; Reuben J; Boldt DH; Rosenblum M; Woodworth T
    Cancer Res; 1993 Sep; 53(17):3930-4. PubMed ID: 8358720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukins in the treatment of mycosis fungoides.
    Gerami P; Guitart J; Rosen S; Kuzel TM
    G Ital Dermatol Venereol; 2008 Feb; 143(1):55-8. PubMed ID: 18833051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
    Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
    Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
    LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC
    Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
    Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.